<ARTICLE> 5
<LEGEND>
This schedule contains summary financial information for the period ended March
31, 1997, restated to reflect the combined results of Incyte Pharmaceuticals,
Inc. and Synteni, Inc.
</LEGEND>
<RESTATED>
<MULTIPLIER> 1,000
       
                             
<PERIOD-TYPE>                   3-MOS
<FISCAL-YEAR-END>                          DEC-31-1997
<PERIOD-START>                             JAN-01-1997
<PERIOD-END>                               MAR-31-1997
<CASH>                                          10,252
<SECURITIES>                                    30,539
<RECEIVABLES>                                    8,678
<ALLOWANCES>                                         0
<INVENTORY>                                          0
<CURRENT-ASSETS>                                52,266
<PP&E>                                          37,648
<DEPRECIATION>                                  11,939
<TOTAL-ASSETS>                                  82,449
<CURRENT-LIABILITIES>                           36,649
<BONDS>                                              0
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                          0
<COMMON>                                            23
<OTHER-SE>                                      45,297
<TOTAL-LIABILITY-AND-EQUITY>                    82,449
<SALES>                                              0
<TOTAL-REVENUES>                                17,998
<CGS>                                                0
<TOTAL-COSTS>                                        0
<OTHER-EXPENSES>                                15,133
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                                   0
<INCOME-PRETAX>                                    509
<INCOME-TAX>                                        52
<INCOME-CONTINUING>                                457
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                       457
<EPS-PRIMARY>                                     0.02
<EPS-DILUTED>                                     0.02